Verified July 2026 · Cited to primary sources
Retatrutide: Evidence Grade B — Real human trials, limited or historical.
The honest verdict
Retatrutide is investigational (Phase 3), not FDA-approved, and not legally available. Human evidence is Grade B — strong published Phase 2 weight-loss data, but not a finished approval. For proven weight loss you can access legally today, see our GLP-1 guidance.
Retatrutide at a glance
- Class
- Investigational GIP/GLP-1/glucagon triple-receptor agonist peptide (Eli Lilly)
- Mechanism
- A triple agonist of the GIP, GLP-1 and glucagon receptors that suppresses appetite and raises energy expenditure to drive weight loss.
- Also known as
- LY3437943, GGG triple agonist
- Research applications
- Obesity / weight loss (published Phase 2 RCT; Phase 3 ongoing)
- Type 2 diabetes (Phase 2 data)
- Forms
- subcutaneous injection
- Legal status
- Research-only
- Evidence grade
- Grade BReal human trials, limited or historical
How we grade evidence
Every grade is assigned by a fixed A–F rubric — human-trial strength, not hype or affiliate status. Last verified July 6, 2026.
What is Retatrutide?
The next-generation weight-loss peptide with the strongest efficacy signal — but it is investigational and not yet available by any legal route.
A triple agonist of the GIP, GLP-1 and glucagon receptors that suppresses appetite and raises energy expenditure to drive weight loss.
How strong is the evidence for Retatrutide?
Grade B: real human trial data (published Phase 2 obesity/T2D RCTs) but not yet FDA-approved and Phase 3 ongoing (rule 3 — real human clinical trials, limited/not-yet-approved). We hold it at B rather than A precisely because approval is not final.
Primary sources (1)
Is Retatrutide legal? (Status July 2026)
No legal supervised US route.
What is Retatrutide used for?
Retatrutide is marketed for the goals below. See how it ranks against other peptides in each — by evidence, not hype.
What does Retatrutide cost — and how do you access it legally?
Typical cost
UNKNOWN (investigational — not commercially available)
Retatrutide is not FDA-approved or commercially available, so there is no legitimate price. We mark it UNKNOWN and do not link gray-market sources.
No legal supervised access route right now.
Retatrutide has no compliant US route today. Vials sold "for research use only" are a gray-market fig-leaf, not a legal loophole — we don't link them. If you pursue Retatrutide, do it with a licensed clinician, and re-check its legal status first.
Trying to lose weight?
For weight loss, an approved GLP-1 beats this peptide.
No research peptide here has proven, legally-available weight-loss data that beats an approved GLP-1. Our sister site compares the options that actually work.
Is Retatrutidesafe? Side effects & risks
Investigational — long-term safety profile still being established in Phase 3. GI side effects consistent with the incretin class reported in trials. Not legally available; any "retatrutide" sold today is gray-market and unverified.
Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.
FAQ
Retatrutide FAQ
Can I get retatrutide right now?
Not legally. Retatrutide is an investigational Eli Lilly drug in Phase 3 trials — it is not FDA-approved and not commercially available. Anything sold as "retatrutide" outside a clinical trial is gray-market and unverified.
How does retatrutide compare to Ozempic or Zepbound?
Retatrutide's Phase 2 obesity data showed substantial weight loss and is one of the most-watched pipeline drugs, but it is still investigational (Grade B — real trials, not yet approved). If you want a proven, legally-available option today, approved GLP-1 medications are the evidence-backed route — see our GLP-1 guidance.
Compare Retatrutide with…
Head-to-head evidence-grade matchups people weigh against Retatrutide.
Keep reading
MOTS-c
An "exercise-mimetic" metabolic peptide — real mechanistic interest, but human evidence is association-only.
Grade ATesamorelin
One of only two FDA-approved peptides in this space — proven to cut visceral fat, but approved for a narrow HIV indication.
Grade APT-141
One of only two FDA-approved peptides in this space — proven to raise sexual desire in premenopausal women, but the benefit is modest and the off-label hype outruns it.
The monthly peptide evidence brief.
What the research and the FDA actually say — one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.